Program
Oxycodone
Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.
Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.
Drug pageOxycodone: every studyMany companies study it; this page follows only the 64 they lead. All 209 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mundipharma | 200 open or running | phase 4since Mar 8, 2011 | Jul 27, 2007 | none ahead |
| Knoa Pharmaits history only | 120 open or running | phase 3since Apr 6, 2006 | Apr 6, 2006 | none ahead |
| Pain Therapeuticsits history only | 120 open or running | phase 3since Mar 13, 2012 | Aug 12, 2008 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Jun 8, 2007 | Jun 8, 2007 | none ahead |
| Egaletits history only | 30 open or running | phase 3since Nov 10, 2015 | Dec 2, 2008 | none ahead |
| Keenova Therapeuticsits history only | 30 open or running | phase 1since Feb 26, 2009 | Feb 26, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| biodelivery-sciences-internationalits history only | 10 open or running | phase 1since Jun 21, 2019 | Jun 21, 2019 | none ahead |
| elite-laboratories-incits history only | 10 open or running | phase 3since Feb 17, 2015 | Feb 17, 2015 | none ahead |
| gl-pharm-tech-corporationits history only | 10 open or running | phase 1since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Indivior Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 16, 2018 | Nov 16, 2018 | none ahead |
| napp-pharmaceuticals-limitedits history only | 10 open or running | phase 4since Nov 3, 2008 | Nov 3, 2008 | none ahead |
| vistapharm-incits history only | 10 open or running | phase 4since Jul 3, 2013 | Jul 3, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mundipharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 27, 2007.
- Feb 23, 2011Phase 3 study in Other Acute Postoperative PainNCT01304134 · 240 enrolled · China
- Mar 8, 2011Phase 4 study in NeoplasmsNCT01313780 · 128 enrolled · Korea, Republic of
- Aug 18, 2011Phase 3 study in PainNCT01438567 · 270 enrolled · United Kingdom
- Sep 21, 2011Phase 3 study in Parkinson DiseaseNCT01439100 · 172 enrolled · Czech Republic, Germany, Hungary and more
- Nov 17, 20112 phase 1 studies in PainNCT01643772, NCT01482936
- Apr 25, 20122 phase 3 studiesNCT01675635, NCT01675622
- Oct 8, 20122 phase 4 studiesNCT01719757, NCT01811238
- Mar 12, 2013Phase 4 study in Chronic PainNCT01811186 · 261 enrolled · Korea, Republic of
- Jun 19, 2013Phase 3 study in NeoplasmsNCT01885182 · 232 enrolled · China
- Aug 5, 2013Phase 3 study in Non Cancer PainNCT01918098 · 230 enrolled · China
- Oct 13, 2014Phase 3 study in Bronchiolitis Obliterans SyndromeNCT02321397 · 155 enrolled · Germany
- Jan 18, 2016Phase 4 study in Cancer PainNCT02660229 · 66 enrolled · Korea, Republic of
- May 22, 2017Phase 4 study in NeoplasmsNCT03176121 · 73 enrolled · Taiwan
- Jun 1, 2017Phase 4 study in NeoplasmsNCT03176199 · 30 enrolled · Taiwan
TargetBeta
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| Methadonerule | Merck | phase 4 | 16 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| axelopranrule | glycyx-therapeutics | phase 2 | 8 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
All 20 Mundipharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03176199Neoplasms · Taiwan | 4 | Completed | Dec 31, 2018 | 30 |
| NCT03176121Neoplasms · Taiwan | 4 | Completed | Dec 31, 2018 | 73 |
| NCT02660229Cancer Pain · Korea, Republic of | 4 | Completed | Jul 2016 | 66 |
| NCT02321397Bronchiolitis Obliterans Syndrome · Germany | 3 | Completed | Mar 2016 | 155 |
| NCT01918098Non Cancer Pain · China | 3 | Completed | Mar 30, 2017 | 230 |
| NCT01885182Neoplasms · China | 3 | Completed | Aug 30, 2015 | 232 |
| NCT01811186Chronic Pain · Korea, Republic of | 4 | Completed | Jan 2014 | 261 |
| NCT01811238Spinal Disorders | 4 | Completed | Apr 2013 | 240 |
| NCT01719757Neoplasms · Korea, Republic of | 4 | Completed | Oct 2013 | 359 |
| NCT01675635Pain, Postoperative | 3 | Completed | Jun 2012 | 240 |
| NCT01675622Neoplasms | 3 | Completed | Jun 2012 | 242 |
| NCT01643772Pain · China | 1 | Completed | Jul 2012 | 61 |
| NCT01482936Pain · China | 1 | Completed | Apr 2011 | 44 |
| NCT01439100Parkinson Disease · Czech Republic, Germany, Hungary and more | 3 | Completed | Aug 2013 | 172 |
| NCT01438567Pain · United Kingdom | 3 | Completed | Feb 2014 | 270 |
| NCT01313780Neoplasms · Korea, Republic of | 4 | Completed | Oct 2013 | 128 |
| NCT01304134Other Acute Postoperative Pain · China | 3 | Completed | Aug 2010 | 240 |
| NCT01167699Pain · Belgium | 3 | Completed | Apr 2011 | 174 |
| NCT00626600Cancer Pain · United Kingdom | 3 | Terminated | May 2009 | 33 |
| NCT00513656Neoplasms · United Kingdom | 2 | Completed | Mar 2010 | 230 |
How it is read
Names in the registry
- “Oxycodone”, 43 entries
- “Reformulated OXY (oxycodone HCl)”, 6 entries
- “Oxycodone/Naloxone”, 5 entries
- “oxycodone hydrochloride”, 4 entries
- “Oxycodone hydrochloride”, 3 entries
Conditions, from the studies’ own filings
- Pain, 15 studies
- Neoplasms, 7 studies
- Osteoarthritis, 4 studies
- Cancer Pain, 3 studies
- Chronic Pain, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.